BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday, Wall Street Zen reports.
Several other equities research analysts also recently weighed in on the stock. JPMorgan Chase & Co. started coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price target for the company. Weiss Ratings began coverage on shares of BlossomHill Therapeutics in a report on Tuesday, November 3rd. They set a “sell (e-)” rating for the company. Guggenheim increased their price objective on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Zacks Research upgraded BlossomHill Therapeutics to a “hold” rating in a research note on Wednesday, September 2nd. Finally, Leerink Partners upped their price objective on BlossomHill Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, September 21st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, BlossomHill Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.00.
Get Our Latest Stock Report on BLSM
BlossomHill Therapeutics Stock Performance
BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.36). Research analysts anticipate that BlossomHill Therapeutics will post -6.04 earnings per share for the current fiscal year.
BlossomHill Therapeutics Company Profile
BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes. The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment. Publicly available information about the company’s leadership and geographic operations is limited.
See Also
- Five stocks we like better than BlossomHill Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
